MPT WWW
Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.

Commentary

Black Box Backfire
Gilbert L. Ross, M.D., Wall Street Journal, 4-21-07

Ross examines how the FDA's 2004 warnings over potential suicide risks for antidepressants in children may have scared some parents away from these drugs, leading to a surge in teen suicides.

That's one conclusion that can be drawn from a new analysis on the benefits and risks of antidepressants for children and adolescents published by the Journal of the American Medical Association. The analysis found that the risks of these medicines are much lower—by a factor of two or more—than the FDA previously thought. It had concluded from a previous study that young people had a 2% risk of having aberrant thoughts if they took antidepressants. The rate is only 0.7%. Further, the study found that these drugs are effective in treating depression and other mental illnesses found in children and teens. The new study, by the way, was undertaken by the National Institutes of Health and the Robert Wood Johnson Foundation—not Big Pharma.

This isn't the what the FDA led us to believe in 2004, when it released an analysis indicating that young people on antidepressants had about a 2% risk, not of suicide, but of "suicidal thoughts." Anti–pharmaceutical activists and some politicians immediately called for major restrictions on antidepressants, simply ignoring that since the introduction of modern SSRI–type medications in the late 1980s, teen suicide rates had steadily fallen. No, the drumbeat from the "no risk allowed" crowd got the attention of the always risk-averse FDA.

The result was a "Black Box" warning—the strongest possible warning short of an outright ban—slapped onto the antidepressants. Remember, this was provoked by an alleged increase in thoughts, not deeds. There were no actual suicides—zero—in the FDA studies, and none in the latest, more extensive analysis.

Guess what happened next? Parents, naturally as frightened by this new warning as they would be by a skull–and–crossbones, decided to forego giving these medicines to their children. Many family doctors, spooked by the prospect of lawsuits, suddenly found other, less effective treatment options more appealing. Primary–care physicians are the ones who prescribe most treatments for depression, not psychiatrists. Since this warning label was introduced, usage of SSRI medications declined by more than 14% from 2004 to 2006 among patients under 19 years old. And, no surprise, actual suicides, not hypothetical ones, increased 18% among youngsters during the first year of the Black Box warnings—the first such increase in many years.

When the FDA was quizzed by renowned psychiatrists—many of whom had disparaged the original warning—spokespersons for the FDA said, in effect, that the new study wasn't surprising and that they weren't forbidding the drugs, merely asking doctors to warn patients and monitor them.



Project FDA.
  
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000
mpt@manhattan-institute.org